

# J David Becherer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10752807/publications.pdf>

Version: 2024-02-01

28  
papers

5,189  
citations

304743

22  
h-index

552781

26  
g-index

28  
all docs

28  
docs citations

28  
times ranked

4496  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor- $\hat{\pm}$ . Nature, 1997, 385, 733-736.	27.8	1,636
2	Regulation of tumour necrosis factor- $\hat{\pm}$ processing by a metalloproteinase inhibitor. Nature, 1994, 370, 558-561.	27.8	583
3	Evidence for a Role of a Tumor Necrosis Factor- $\hat{\pm}$ (TNF- $\hat{\pm}$ )-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival. Journal of Biological Chemistry, 1999, 274, 13613-13618.	3.4	374
4	Intracellular maturation and localization of the tumour necrosis factor $\hat{\pm}$ convertase (TACE). Biochemical Journal, 2000, 347, 131-138.	3.7	320
5	Metalloproteinase Inhibitors for the Disintegrin-Like Metalloproteinases ADAM10 and ADAM17 that Differentially Block Constitutive and Phorbol Ester-Inducible Shedding of Cell Surface Molecules. Combinatorial Chemistry and High Throughput Screening, 2005, 8, 161-171.	1.1	293
6	Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity. Journal of Biological Chemistry, 1999, 274, 3531-3540.	3.4	284
7	The Tumor Necrosis Factor- $\hat{\pm}$ Converting Enzyme (TACE): A Unique Metalloproteinase with Highly Defined Substrate Selectivity. Biochemistry, 2002, 41, 9462-9469.	2.5	190
8	ADAM10 is a principal 'sheddase' of the low-affinity immunoglobulin E receptor CD23. Nature Immunology, 2006, 7, 1293-1298.	14.5	189
9	Altered Tumor Necrosis Factor- $\hat{\pm}$ (TNF- $\hat{\pm}$ ) Processing in Adipocytes and Increased Expression of Transmembrane TNF- $\hat{\pm}$ in Obesity. Diabetes, 2002, 51, 1876-1883.	0.6	165
10	Specific Sequence Elements Are Required for the Expression of Functional Tumor Necrosis Factor- $\hat{\pm}$ -converting Enzyme (TACE). Journal of Biological Chemistry, 1999, 274, 30563-30570.	3.4	145
11	Evidence for a Critical Role of the Tumor Necrosis Factor $\hat{\pm}$ Convertase (TACE) in Ectodomain Shedding of the p75 Neurotrophin Receptor (p75NTR). Journal of Biological Chemistry, 2004, 279, 4241-4249.	3.4	134
12	The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Letters, 2002, 524, 154-158.	2.8	128
13	Catalytic Properties of ADAM19. Journal of Biological Chemistry, 2003, 278, 22331-22340.	3.4	114
14	Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 3548-3571.	6.4	103
15	Intracellular maturation and localization of the tumour necrosis factor $\hat{\pm}$ convertase (TACE). Biochemical Journal, 2000, 347, 131.	3.7	89
16	Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Current Topics in Developmental Biology, 2003, 54, 101-123.	2.2	81
17	Design of Selective and Soluble Inhibitors of Tumor Necrosis Factor- $\hat{\pm}$ Converting Enzyme (TACE). Journal of Medicinal Chemistry, 2001, 44, 4252-4267.	6.4	70
18	Different ADAMs have distinct influences on Kit ligand processing: phorbol-ester-stimulated ectodomain shedding of Kitl1 by ADAM17 is reduced by ADAM19. Journal of Cell Science, 2007, 120, 943-952.	2.0	56

#	ARTICLE	IF	CITATIONS
19	Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor,) Tj ETQq1 1 0.784314 rgBT <sub>45</sub> /Overl	2.9	45
20	Cell Surface Proteins Reacting with Activated Complement Components. Complement and Inflammation, 1989, 6, 142-165.	0.7	43
21	Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38. Journal of Medicinal Chemistry, 2015, 58, 7021-7056.	6.4	41
22	The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3. FEBS Letters, 2002, 520, 102-106.	2.8	33
23	Substrate Specificity and Novel Selective Inhibitors of TNF-&#945; Converting Enzyme (TACE) from Two-Dimensional Substrate Mapping. Combinatorial Chemistry and High Throughput Screening, 2005, 8, 327-339.	1.1	24
24	CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. Science Advances, 2022, 8, .	10.3	21
25	Complementary NAD <sup>+</sup> replacement strategies fail to functionally protect dystrophin-deficient muscle. Skeletal Muscle, 2020, 10, 30.	4.2	15
26	TNF± converting enzyme. , 1999, , 187-203.		7
27	Orally Bioavailable Enzymatic Inhibitor of CD38, <b>MK-0159</b>, Protects against Ischemia/Reperfusion Injury in the Murine Heart. Journal of Medicinal Chemistry, 2022, 65, 9418-9446.	6.4	4
28	A high throughput assay for the TNF converting enzyme. , 2000, , 87-100.		2